Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Iowa Zoryve Coverage | Open…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.05.24

    Zoryve (roflumilast) topical therapy coverage

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.24 alerts

    Get alerted when Policy 05.05.24 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Zoryve cream and foam used to treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis when applicable age, diagnosis, prior-treatment response or intolerance, quantity, and continuation requirements are met.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyZoryve (roflumilast) topical therapy coverage
    Policy CodePolicy 05.05.24
    Change TypeNo material change
    Effective DateOctober 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the requested formulation, strength, diagnosis, patient age, and required prior-treatment response or intolerance documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Covered formulation and age combinations
    6 monthsInitial approval
    12 monthsContinuation approval
    60 g/30 daysStandard quantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    120 g/30 days
    Additional cream quantity

    Zoryve Coverage Criteria

    Initial therapy - Zoryve 0.3% cream for plaque psoriasis

    Covered when all of the following are met:

    Zoryve 0.3% cream initial therapy

    • Indication and age: The requested drug is prescribed for topical treatment of plaque psoriasis in a patient 2 years of age or older.Age >=2 years
    • Prior regimens: The patient has experienced an inadequate treatment response or intolerance to at least two of the specified topical regimens, unless all options are contraindicated.At least 2 regimens

      Specified regimens include: (1) a high- to super-high-potency generic topical corticosteroid used concurrently with generic topical calcipotriene cream or solution; (2) generic topical calcipotriene/betamethasone suspension; or (3) a high- to ultrahigh-potency topical corticosteroid used concurrently with generic tazarotene 0.1% cream.

    Initial therapy - Zoryve 0.15% cream for atopic dermatitis

    Covered when all of the following are met:

    Zoryve 0.15% cream initial therapy

    • Indication and age: The requested drug is prescribed for topical treatment of mild to moderate atopic dermatitis in a patient 6 years of age or older.Age >=6 years
    • Prior regimens: The patient has experienced an inadequate treatment response or intolerance to at least one of the specified topical regimens, unless all options are contraindicated.At least 1 regimen

      Specified regimens are a topical calcineurin inhibitor with a medium- or higher-potency topical corticosteroid, or a topical calcineurin inhibitor alone.

    Initial therapy - Zoryve 0.05% cream for atopic dermatitis

    Covered when all of the following are met:

    Zoryve 0.05% cream initial therapy

    • Indication and age: The requested drug is prescribed for topical treatment of mild to moderate atopic dermatitis in a patient 2 to 5 years of age.Age 2-5 years
    • Prior therapies: The patient has experienced an inadequate treatment response or intolerance to at least one topical calcineurin inhibitor or a medium- or higher-potency topical corticosteroid, unless all options are contraindicated.At least 1 therapy

    Initial therapy - Zoryve 0.3% foam for seborrheic dermatitis

    Covered when all of the following are met:

    Zoryve 0.3% foam initial therapy for seborrheic dermatitis

    • Indication and age: The requested drug is prescribed for topical treatment of seborrheic dermatitis in a patient 9 years of age or older.Age >=9 years
    • Prior therapy: The patient has experienced an inadequate treatment response or intolerance to an antifungal alone or in combination with a high-potency generic topical corticosteroid, unless all options are contraindicated.

      Examples of antifungals include ketoconazole, another azole, or ciclopirox; examples of high-potency generic topical corticosteroids include betamethasone dipropionate, clobetasol, fluocinonide, or halobetasol.

    Initial therapy - Zoryve 0.3% foam for plaque psoriasis

    Covered when all of the following are met:

    Zoryve 0.3% foam initial therapy for plaque psoriasis

    • Indication and age: The requested drug is prescribed for topical treatment of plaque psoriasis in a patient 12 years of age or older.Age >=12 years
    • Prior regimens: The patient has experienced an inadequate treatment response or intolerance to at least two of the specified topical regimens, unless all options are contraindicated.At least 2 regimens

      Specified regimens include: (1) a high- to super-high-potency generic topical corticosteroid used concurrently with generic topical calcipotriene cream or solution; (2) generic topical calcipotriene/betamethasone suspension; or (3) a high- to ultrahigh-potency topical corticosteroid used concurrently with generic tazarotene 0.1% cream.

    Continuation therapy

    Covered when all of the following are met:

    Continuation therapy: The patient has achieved or maintained a positive clinical response to Zoryve, evidenced by improvement in signs and symptoms from baseline.Improvement from baseline

    Examples include improvement in itching, redness, flaking, scaling, burning, cracking, or pain. Approval is for 12 months with a quantity limit of 60 grams per 30 days. Coverage for 120 grams per 30 days is available for Zoryve cream when the treated body surface area requires more than 60 grams per month.

    Initial Approval by Formulation and Indication

    Zoryve 0.3% cream - plaque psoriasis

    Initial approval may be considered medically necessary when all of the following are met:

    0.3% cream for plaque psoriasis

    • Indication and age: The requested drug is prescribed for topical treatment of plaque psoriasis in a patient 2 years of age or older.Age >=2 years
    • Prior regimens: Inadequate treatment response or intolerance to at least two specified topical regimens, unless all options are contraindicated.At least 2 regimens

      The specified regimens are a high- to super-high-potency generic topical corticosteroid with generic topical calcipotriene cream or solution; generic topical calcipotriene/betamethasone suspension; or a high- to ultrahigh-potency topical corticosteroid with generic tazarotene 0.1% cream.

    Continuation of Therapy

    Continuation of therapy

    Continuation may be considered medically necessary when all of the following are met:

    Positive clinical response: The patient has achieved or maintained a positive clinical response to therapy, evidenced by improvement in signs and symptoms from baseline.Improvement from baseline

    Examples include improvement in itching, redness, flaking, scaling, burning, cracking, or pain. Approval is for 12 months with a quantity limit of 60 grams per 30 days. Coverage for 120 grams per 30 days is available for Zoryve cream when the treated body surface area requires more than 60 grams per month.

    Required Prior Topical Therapy

    Condition and formulationRequired prior therapy
    Plaque psoriasis — Zoryve 0.3% cream or 0.3% foamInadequate treatment response or intolerance to at least two of the following: (1) a high- to super-high-potency generic topical corticosteroid used concurrently with generic topical calcipotriene cream or solution; (2) generic topical calcipotriene/betamethasone suspension; or (3) a high- to ultrahigh-potency topical corticosteroid used concurrently with generic tazarotene 0.1% cream.
    Condition and formulationRequired prior therapy
    Mild to moderate atopic dermatitis — Zoryve 0.15% cream; patients 6 years of age and olderInadequate treatment response or intolerance to at least one of the following: a topical calcineurin inhibitor and a medium- or higher-potency topical corticosteroid, or a topical calcineurin inhibitor alone.
    Condition and formulationRequired prior therapy
    Mild to moderate atopic dermatitis — Zoryve 0.05% cream; patients 2 to 5 years of ageInadequate treatment response or intolerance to at least one of the following: a topical calcineurin inhibitor, or a medium- or higher-potency topical corticosteroid.
    Condition and formulationRequired prior therapy
    Seborrheic dermatitis — Zoryve 0.3% foamInadequate treatment response or intolerance to an antifungal alone or in combination with a high-potency generic topical corticosteroid.

    Formulation-Specific Quantity Limits

    Zoryve 0.3% cream quantity limit
    FormulationZoryve (roflumilast) 0.3% cream
    Standard quantity limit60 grams per 30 days
    Additional cream quantityUp to 120 grams per 30 days when treating a body surface area requiring more than 60 grams per month
    Zoryve 0.15% cream quantity limit
    FormulationZoryve (roflumilast) 0.15% cream
    Standard quantity limit60 grams per 30 days
    Additional cream quantityUp to 120 grams per 30 days when treating a body surface area requiring more than 60 grams per month

    Quantity and Dispensing Rules

    Standard Zoryve quantity limit
    Standard limit60 grams per 30 days
    Applies toZoryve cream and foam formulations
    Continuation therapyApproval is subject to a quantity limit of 60 grams per 30 days
    Additional cream quantity
    Maximum cream quantity120 grams per 30 days
    EligibilityThe treated body surface area must require more than 60 grams of cream per month
    DocumentationRequests exceeding 60 grams per 30 days must document the treated body surface area requirement

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Zoryve (roflumilast). The requested formulation and strength must match a covered indication, the member must meet the applicable minimum age, and all formulation-specific approval criteria must be satisfied.

    • 0.3% cream: plaque psoriasis, age 2 years or older.
    • 0.15% cream: mild to moderate atopic dermatitis, age 6 years or older.
    • 0.05% cream: mild to moderate atopic dermatitis, age 2–5 years.
    • 0.3% foam: seborrheic dermatitis, age 9 years or older, or plaque psoriasis, age 12 years or older.
    Step Therapy

    Psoriasis Step Therapy

    For Zoryve cream or foam requested for plaque psoriasis, document inadequate response or intolerance to at least two required topical regimens, unless all options are contraindicated.

    Therapy Overview

    Zoryve (roflumilast) is a topical phosphodiesterase-4 (PDE4) inhibitor used for inflammatory dermatologic conditions. The policy addresses formulation- and age-specific coverage for plaque psoriasis, mild to moderate atopic dermatitis, and seborrheic dermatitis.

    Covered formulations include 0.3% cream for plaque psoriasis in patients 2 years of age and older; 0.15% cream for mild to moderate atopic dermatitis in patients 6 years of age and older; 0.05% cream for mild to moderate atopic dermatitis in patients 2 to 5 years of age; and 0.3% foam for seborrheic dermatitis in patients 9 years of age and older or plaque psoriasis of the scalp and body in patients 12 years of age and older. Initial coverage generally requires an inadequate response or intolerance to specified topical therapies, while continuation requires documented improvement from baseline.

    Policy Terms

    Zoryve (roflumilast)
    DrugZoryve (roflumilast)
    Drug classTopical phosphodiesterase-4 (PDE4) inhibitor
    Formulations0.3% cream, 0.15% cream, 0.05% cream, and 0.3% foam
    Covered conditionsPlaque psoriasis, mild to moderate atopic dermatitis, and seborrheic dermatitis
    Age rangesCream: age 2 years and older for plaque psoriasis; age 6 years and older for 0.15% cream; age 2 to 5 years for 0.05% cream. Foam: age 9 years and older for seborrheic dermatitis and age 12 years and older for plaque psoriasis
    Additional-quantity body surface area
    Definition
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyZoryve (roflumilast) topical therapy coverage
    Policy CodePolicy 05.05.24
    Change TypeNo material change
    Effective DateOctober 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the requested formulation, strength, diagnosis, patient age, and required prior-treatment response or intolerance documentation.
    SourceLink
    On This Page
    Zoryve Coverage CriteriaInitial Approval by Formulation and IndicationContinuation of TherapyRequired Prior Topical TherapyFormulation-Specific Quantity LimitsQuantity and Dispensing RulesAuthorization, Documentation, and Denial RisksTherapy OverviewPolicy Terms

    Zoryve 0.15% cream - atopic dermatitis

    Initial approval may be considered medically necessary when all of the following are met:

    0.15% cream for atopic dermatitis

    • Indication and age: The requested drug is prescribed for topical treatment of mild to moderate atopic dermatitis in a patient 6 years of age or older.Age >=6 years
    • Prior regimen: Inadequate treatment response or intolerance to at least one specified topical calcineurin inhibitor-based regimen, unless all options are contraindicated.At least 1 regimen

      The specified regimens are a topical calcineurin inhibitor with a medium- or higher-potency topical corticosteroid, or a topical calcineurin inhibitor alone.

    Zoryve 0.05% cream - atopic dermatitis

    Initial approval may be considered medically necessary when all of the following are met:

    0.05% cream for atopic dermatitis

    • Indication and age: The requested drug is prescribed for topical treatment of mild to moderate atopic dermatitis in a patient 2 to 5 years of age.Age 2-5 years
    • Prior therapy: Inadequate treatment response or intolerance to at least one topical calcineurin inhibitor or a medium- or higher-potency topical corticosteroid, unless all options are contraindicated.At least 1 therapy

    Zoryve 0.3% foam - seborrheic dermatitis

    Initial approval may be considered medically necessary when all of the following are met:

    0.3% foam for seborrheic dermatitis

    • Indication and age: The requested drug is prescribed for topical treatment of seborrheic dermatitis in a patient 9 years of age or older.Age >=9 years
    • Prior therapy: Inadequate treatment response or intolerance to an antifungal alone or combined with a high-potency generic topical corticosteroid, unless all options are contraindicated.

      Examples of antifungals include ketoconazole, another azole, or ciclopirox.

    Zoryve 0.3% foam - plaque psoriasis

    Initial approval may be considered medically necessary when all of the following are met:

    0.3% foam for plaque psoriasis

    • Indication and age: The requested drug is prescribed for topical treatment of plaque psoriasis in a patient 12 years of age or older.Age >=12 years
    • Prior regimens: Inadequate treatment response or intolerance to at least two specified topical regimens, unless all options are contraindicated.At least 2 regimens

      The specified regimens are a high- to super-high-potency generic topical corticosteroid with generic topical calcipotriene cream or solution; generic topical calcipotriene/betamethasone suspension; or a high- to ultrahigh-potency topical corticosteroid with generic tazarotene 0.1% cream.

    Zoryve 0.05% cream quantity limit
    FormulationZoryve (roflumilast) 0.05% cream
    Standard quantity limit60 grams per 30 days
    Additional cream quantityUp to 120 grams per 30 days when treating a body surface area requiring more than 60 grams per month
    Zoryve 0.3% foam quantity limit
    FormulationZoryve (roflumilast) 0.3% foam
    Quantity limit60 grams per 30 days
    Additional quantityNo additional quantity is specified for the foam formulation
  1. High- to super-high-potency generic topical corticosteroid used concurrently with generic topical calcipotriene cream or solution.
  2. Generic topical calcipotriene/betamethasone suspension.
  3. High- to ultrahigh-potency topical corticosteroid used concurrently with generic tazarotene 0.1% cream.
  4. Step Therapy

    Atopic Dermatitis Step Therapy: Age 6 and Older

    For 0.15% cream requested for mild to moderate atopic dermatitis in a patient age 6 years or older, document inadequate response or intolerance to at least one required topical calcineurin inhibitor-based regimen, unless all options are contraindicated.

    • Topical calcineurin inhibitor used with a medium- or higher-potency topical corticosteroid, or topical calcineurin inhibitor alone.
    Step Therapy

    Atopic Dermatitis Step Therapy: Age 2–5 Years

    For 0.05% cream requested for mild to moderate atopic dermatitis in a patient age 2–5 years, document inadequate response or intolerance to at least one required topical regimen, unless all options are contraindicated.

    • Topical calcineurin inhibitor, or a medium- or higher-potency topical corticosteroid.
    Step Therapy

    Seborrheic Dermatitis Step Therapy

    For 0.3% foam requested for seborrheic dermatitis in a patient age 9 years or older, document inadequate response or intolerance to the required antifungal-based therapy, unless all options are contraindicated.

    • Antifungal therapy, such as ketoconazole, another azole, or ciclopirox, used alone or with a high-potency generic topical corticosteroid.
    Documentation Required

    Initial-Therapy Documentation

    For initial approval, submit clinical documentation identifying the requested Zoryve formulation and strength, diagnosis, patient age, and the applicable prior-treatment response or intolerance.

    • Document the relevant prior topical therapies, inadequate response or intolerance, and any contraindications when step therapy is required.
    • Confirm the diagnosis and age support the requested formulation-specific indication.
    Documentation Required

    Additional Quantity Documentation

    When requesting more than the standard cream quantity, document that the body surface area being treated requires more than 60 grams per 30 days. A supported cream exception permits coverage of up to 120 grams per 30 days.

    • The additional-quantity exception applies to Zoryve 0.3%, 0.15%, and 0.05% cream.
    • The standard quantity limit is 60 grams per 30 days; the 0.3% foam limit remains 60 grams per 30 days.
    Documentation Required

    Continuation Response Documentation

    For continuation therapy, document that the patient has achieved or maintained a positive clinical response, evidenced by improvement in signs and symptoms from baseline.

    • Examples include improvement in itching, redness, flaking, scaling, burning, cracking, or pain.
    • Continuation approval is for 12 months, subject to the applicable quantity limit.
    Denial Risk

    Failure to Meet Criteria May Result in Denial

    Coverage may be denied when the requested formulation, indication, patient age, or required step-therapy criteria are not supported by the submitted documentation.

    • Initial approval criteria must be met for the specific Zoryve formulation and diagnosis.
    • Required inadequate response or intolerance must be documented unless all listed options are contraindicated.
    Denial Risk

    Quantity Limit Denial Risk

    Requests exceeding the applicable quantity limit may be denied unless documentation supports the cream quantity exception based on treated body surface area.

    • Standard limit: 60 grams per 30 days for all Zoryve formulations.
    • Cream quantities up to 120 grams per 30 days may be covered when documentation shows the treated body surface area requires more than 60 grams per 30 days.
    • The 120-gram exception does not apply to 0.3% foam.
    Denial Risk

    Samples and Assistance Programs Do Not Bypass Criteria

    Members currently using Zoryve samples or receiving it through the manufacturer’s patient assistance program must still meet all initial-approval criteria. Sample or assistance-program access does not bypass prior authorization requirements.

    • Submit the same formulation-specific indication, age, step-therapy, and quantity documentation required for initial approval.
    Billing Rule

    Benefit and Dosing Limitations

    Coverage is subject to the member’s benefit, contract limitations, applicable exclusions or exceptions, and the presence of an available benefit. Approvals and dosing must also remain consistent with FDA-approved labeling, accepted compendia, and evidence-based practice guidelines.

    • Verify individual member benefits and applicable contract language; this policy may not apply to the Federal Employee Program.
    • Wellmark determines medical necessity only when the benefit exists and no contract exclusion applies.
    • Dosing limits may apply even when medical-necessity criteria are met.
    The treated body surface area requiring more than 60 grams of a Zoryve cream formulation per month
    Standard cream quantity60 grams per 30 days
    Additional quantity supportedUp to 120 grams per 30 days